CV (CapsoVision) ROCE %: -165.34% (As of Mar. 2026)


CV CapsoVision Inc CV
10 GF Score
Price $6.99
! 1 Warning Sign
View Full Analysis

What is CapsoVision ROCE %?

CapsoVision CV 10 ROCE % is -165.34% as of Mar. 2026. GuruFocus rates CV with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CapsoVision's annualized ROCE % for the quarter that ended in Mar. 2026 was -165.34%.

CapsoVision  (NAS:CV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CapsoVision ROCE % Related Terms

CapsoVision ROCE % Historical Data

* Premium members only.

The historical data trend for CapsoVision's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CapsoVision ROCE % Chart

CapsoVision Annual Data
Trend Dec23 Dec24 Dec25
ROCE %
-56.68 -113.74 -177.57

CapsoVision Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only -174.20 -247.39 -243.44 -171.77 -165.34
CV
10GF Score
CapsoVision Inc CV
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CapsoVision ROCE % Calculation

CapsoVision's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-25.516/( ( (16.803 - 1.801) + (18.164 - 4.427) )/ 2 )
=-25.516/( (15.002+13.737)/ 2 )
=-25.516/14.3695
=-177.57 %

CapsoVision's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-28.372/( ( (18.164 - 4.427) + (25.945 - 5.363) )/ 2 )
=-28.372/( ( 13.737 + 20.582 )/ 2 )
=-28.372/17.1595
=-165.34 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -165.34% mean?
CapsoVision (CV) has a ROCE % of -165.34% as of Mar. 2026.
Is CapsoVision's ROCE % too high?
CapsoVision's current ROCE % is -165.34%. Overall, CapsoVision has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does CapsoVision's ROCE % compare to SENS and MASS?
CapsoVision's ROCE % of -165.34% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CapsoVision's current ROCE % is -165.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CapsoVision stock overvalued right now?
CapsoVision (CV) has a current ROCE % of -165.34%. The current ROCE % is -165.34%. CapsoVision's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For CapsoVision (CV), the current ROCE % is -165.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CapsoVision Business Description

Other Exchanges H6U:Germany
Address 18805 Cox Avenue, Suite 250, Saratoga, CA, USA, 95070
CapsoVision Inc is a commercial-stage medical technology enterprise that innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. The company's core technology platform is an orally ingestible capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. CapsoVision's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D, directed at the large intestines. Geographically, the company generates the majority of its revenue from the United States.
10GF Score

Get the complete analysis for CV

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.99
Price